New treatments attacking cancer at molecular level.
Bloomberg News (3/5, Wells, Pettypiece) reports on how Sutent (sutinib) "is part of an explosion of treatments that attack cancer at the molecular level, holding the promise of turning intractable malignancies into chronic diseases like diabetes or HIV." Bloomberg adds that these therapies "are already extending life -- and adding to the cost of end-of-life care, which in the case of Sutent could be on the order of $48,720 a year." But due to Sutent's and other similar drugs' "limited periods of effectiveness," they are "so expensive that some governments resist paying for them."
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment